Hybrid Nanoplatforms for Theranostics Nanomedicine 2.0
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 136
Special Issue Editor
Interests: cancer nanotechnology; hybrid nanostructures; antibacterial nanomedicine; drug delivery; tumor imaging; nanomedicine for infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanomedicine, the therapeutic branch of nanotechnology, has reached next generation clinical advances, and many nanomedicine products have been approved for cancer and infectious disease therapies. Hybrid nanoplatforms are capable of performing additional therapeutic modality in cancer and infectious disease management. The therapeutic modalities include early detection of the diseased cells, disease diagnosis, drug loading and delivery, external and internal stimuli responsive drug delivery, therapy, and therapy monitoring. A number of hybrid nanoplatforms have been developed to fight cancer and deadly pathogens; these hybrid nanoplatform include organic nanostructures, polymers, liposomes, lipids, inorganic nanostructures, gold nanoparticles, magnetic materials, silica nanoparticles, silver nanoparticles, titanium dioxide nanoparticles, biomolecules, protein, DNA nanostructures, antimicrobial peptides, metallic nanoparticles, and antiviral hybrid platforms.
Dr. Nanasaheb Thorat
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- organic nanostructures
- inorganic nanostructures
- hybrid organic-inorganic nanostructures
- biomolecules
- antimicrobial nanostructures
- nanotheranostics (diagnostics + theranostics)
- hybrid nanostructures for imaging
- therapy monitoring
- magnetic hyperthermia
- photodynamic and photothermal therapy
- ultrasound therapy
